Abstract: Molecular targeted therapy plays an important role in the treatment of gastrointestinal cancer. In recent years, a large number of targeted drugs have been developed and tested in clinical trials to verify their efficacy and security. The better efficacy and security of targeted drugs represented by monoclonal antibodies and tyrosine kinase inhibitors have been demonstrated in each phase of clinical trials.

Key words: Gastrointestinal neoplasms, Antibodies, monclonal, Tyrosine kinase inhibitors, Targeted therapy